CytomX Therapeutics Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- CytomX Therapeutics's estimated annual revenue is currently $59.5M per year.
- CytomX Therapeutics received $70.0M in venture funding in June 2015.
- CytomX Therapeutics's estimated revenue per employee is $334,281
- CytomX Therapeutics's total funding is $184.4M.
- CytomX Therapeutics has 178 Employees.
- CytomX Therapeutics grew their employee count by 24% last year.
- CytomX Therapeutics currently has 32 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Online Review||Pricing|
What Is CytomX Therapeutics?
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company's pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company, MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.keywords:Biotechnology,Healthcare,Human Resources Hr,Pharmaceuticals
Number of Employees
Employee Growth %
CytomX Therapeutics News
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused ...
What just happened? CytomX Therapeutics, Inc. (NASDAQ:CTMX) stock value has plummeted by nearly -4.05% or (-0.36 points) to $8.52 from ...
CytomX Therapeutics Inc (NASDAQ:CTMX) has received a consensus recommendation of “Buy” from the fourteen brokerages that are covering ...
CytomX Therapeutics Funding
|2015-01-07||$20.0M||C||Pfizer Venture Investments||Article|
|2015-06-17||$70.0M||D||Fidelity Management & Research Company||Article|
CytomX Therapeutics Executive Hires
|2010-11-22||Ajay Chadha||Chief Scientific Officer||Article|
|2011-01-06||Sean McCarthy||Chief Business Officer||Article|
|2011-10-07||Henry Lowman||Chief Scientific Officer||Article|
|2013-07-17||Krishna Polu||Chief Medical Officer||Article|
|2015-01-06||W. Michael Kavanaugh||Chief Scientific Officer/Head Research/Early Development||Article|
|2015-05-28||Bob Goeltz||Chief Financial Officer||Article|
|2015-08-04||Debanjan Ray||senior vice president of corporate development and strategy||Article|
|2017-05-17||Debanjan Ray||CFO/Head Corporate Development||Article|